


This listing of the claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1. (Currently amended) A Combination which comprises nateglinide of formula (I)



and (a) an antidiabetic phenylacetic acid derivative or (b) acarbose in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; ~~for simultaneous, separate or sequential use.~~

2. (Currently amended) The Combination according to claim 1 ~~wherein is a combined preparation or a pharmaceutical composition~~ the active ingredients and the pharmaceutically acceptable carrier are all administered simultaneously.

3. (Currently amended) The Combination according to claim 21 ~~wherein is a combined preparation for simultaneous, separate or sequential use in the prevention or treatment of diseases.~~ the active ingredients are administered separately

4. (Currently amended) The Combination according to any one of claim 1 wherein the combination comprises the antidiabetic phenylacetic acid derivative repaglinide or a pharmaceutically acceptable salt thereof.

5. (Currently amended) The Combination according to any one of claim 1, comprising nateglinide and ~~characterized in that the combination comprises acarbose.~~

6. (Currently amended) The Combination according to any one of claim 1, ~~characterized in that~~ wherein the combination comprises at least one further pharmaceutically active compound selected from the group consisting of antidiabetic thiazolidinediones, sulphonyl urea derivatives, metformin, and insulin, or the pharmaceutically acceptable salts of such compounds where possible; or at least one further antidiabetic additional phenylacetic acid derivative or a pharmaceutically acceptable salt thereof.

7. (Currently amended) The Combination according to any one of claim 1, characterized in ~~that~~wherein nateglinide is present in the B-type or H-type crystal modification.

8. (Canceled)

9. (Currently amended) A Method of treatment of a warm-blooded animal having metabolic disorders comprising administering to the animal a therapeutically effective amount of a combination of nateglinide and (a) an antidiabetic-phenylacetic acid derivative or (b) acarbose in ~~a quantity which is jointly therapeutically effective against metabolic disorders in which the compounds can also be present in the form of their or their~~ pharmaceutically acceptable salts.

10. (Canceled)

11. (Canceled)

12. (Canceled)

13. (original) A commercial package comprising as active agents nateglinide and (a) an antidiabetic-phenylacetic acid derivative or (b) acarbose, together with instructions for simultaneous, separate or sequential use thereof in the ~~prevention, delay of progression or treatment of metabolic disorders or in a method of improving the bodily appearance of a~~ mammal.

14. (Currently amended) The Combination according to claim 2, wherein the combination comprises the antidiabetic-phenylacetic acid derivative repaglinide or a pharmaceutically acceptable salt thereof.

15. (Currently amended) The Combination according to claim 2, ~~characterized in that~~wherein the combination comprises acarbose.

16. (Currently amended) The Combination according to claim 2, ~~characterized in that~~wherein the combination comprises at least one further pharmaceutically active compound selected from the group consisting of antidiabetic thiazolidinediones, sulphonyl urea derivative, metformin, and insulin, or the pharmaceutically acceptable salts of such compounds where possible; or at least one further antidiabetic phenylacetic acid derivative or a pharmaceutically acceptable salt thereof.

17. (Currently amended) The Combination according to claim 2, ~~characterized in that~~ wherein

nateglinide is present in the B-type of H-type crystal modification.

18. (Currently amended) A Method of treating obesity ~~improving the bodily appearance of a mammal which comprises~~ orally administering to said mammal ~~at the~~ combination according to claim 2 ~~to~~ in a dosage effective to influence the glucose metabolism, and repeating said dosage until a cosmetically beneficial loss of body weight has occurred mammal in need thereof.

19. (Currently amended) A pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against metabolic disorders, of ~~a~~ the combination according to claim 2, and at least one pharmaceutically acceptable carrier.

20. (Canceled)

21. (Canceled)

22. (New) A method of treating metabolic disorders comprising administer a therapeutically effective amount of the combination of claim 1 to a mammal in need thereof.

23. (New) A method of treating obesity comprising administering a therapeutically effective amount of the combination of claim 1 to a mammal in need thereof.